-+ 0.00%
-+ 0.00%
-+ 0.00%

Altimmune's Topline Results From IMPACT Phase 2b Trial Of Pemvidutide For Metabolic Dysfunction-Associated Steatohepatitis Showed Improvement In Antifibrotic Activity With Both Treatment Doses

Benzinga·12/19/2025 11:32:41
Listen to the news
  • Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint
  • Additional weight loss from 24 to 48 weeks with 1.8 mg dose, without plateauing
  • Favorable tolerability profile of pemvidutide preserved at 48 weeks, reinforced by low treatment-related discontinuation rate
  • End-of-Phase 2 meeting with FDA supports advancing to registrational Phase 3 trial in MASH patients with moderate to advanced liver fibrosis